Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Stangl

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 30, 2014
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS studyFrank Lehner, Klemens Budde, Martin Zeier, et al.
Clinical Nephrology|March 3, 2016
Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trialClaudia Sommerer, Klemens Budde, Martin Zeier, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 30, 2014
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS studyFrank Lehner, Klemens Budde, Martin Zeier, et al.
Clinical Nephrology|March 3, 2016
Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trialClaudia Sommerer, Klemens Budde, Martin Zeier, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Pageof 5